IDENTIFICATION OF DRUG RELATED PROBLEMS (DRPS) IN THE TREATMENT OF ALZHEIMER'S PATIENTS AT RSUP DR. HASAN SADIKIN BANDUNG
Alzheimer's disease is a progressive condition with unknown causes, characterized by a loss of cognitive and physical functions, typically accompanied by behavioural changes. One of the risk factors for Alzheimer's disease is age, specifically being over 65 years old (elderly). In the elde...
Saved in:
| Main Author: | |
|---|---|
| Format: | Final Project |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/82348 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Alzheimer's disease is a progressive condition with unknown causes, characterized by a loss of cognitive and physical functions, typically accompanied by behavioural changes. One of the risk factors for Alzheimer's disease is age, specifically being over 65 years old (elderly). In the elderly, a decline in bodily functions could occur, potentially leading to various morbidities, necessitating multiple medications. The extensive use of medications could lead to drug-related problems (DRPs), events or conditions involving medication therapy that could or potentially interfere with the desired therapeutic outcomes. This research aimed to identify the incidence of DRPs in Alzheimer patients at Dr. Hasan Sadikin General Hospital, Bandung, during the years 2022-2023. This research was non-experimental observational research with a descriptive research design. The research data was retrospective data taken from patient medical records for the period January 2022 to December 2023. The data obtained was identified based on the PCNE V9.1 classification and the literature. The results of the study showed that there were DRPs, namely 38.10% drug interactions, 28.57% indications without medication, 19.05% incorrect or unclear administration time instructions, 9.52% dosing regimens do not frequent enough, 9.52% drugs without indication, 9.52% subdose, 4.76% formulary inaccuracy, and 4.76% overdose. Comorbidities and the number of drugs used did not have a significant relationship with the incidence of DRPs. Thus, careful monitoring is still needed in therapy for Alzheimer's disease patients.
|
|---|